The role of chemotherapy in the management of celomic epithelial carcinoma of the ovary

Cancer Investigation

Volumn 15, Issue 3, 1997, Pages 277-287

  Thigpen, Tate ^a,c   Vance, Ralph ^a   Khansur, Tawfiq ^a,b   Malamud, Fernando ^a,b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b Medical Center   (United States)

^c UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; PLATINUM;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; DNA CONTENT; DOSE RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; OVARY CARCINOMA; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT PLANNING;

EID: 0030903817     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909709039727     Document Type: Article

References (36)

1. Boring C, Squires T, Tong T, Montgomery S: Cancer statistics, 1994. CA 44:7-26, 1994.
2. The new FIGO state grouping for primary carcinoma of the ovary (1985). Gynecol Oncol 25:383, 1986.
3. Hoskins WJ: Surgical staging and cytoreductive surgery of epithelial ovarian cancer. Cancer 71:1534-1540, 1993.
4. van der Burg MEL, van Lent M, Kobierska A, et al: Intervention debulking surgery does improve survival in advanced epithelial ovarian cancer: an EORTC Gynecological Cancer Cooperative Group study. Proc ASCO 12:258, 1993.
5. Thigpen JT: Single agent chemotherapy in the management of ovarian carcinoma. In: Ovarian Carcinoma, edited by DS Alberts, EA Surwit, Boston, Martinus Nijhoff, 1985, pp 115-146.
6. Omura G, Morrow P, Blessing J, et al: A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma. Cancer 51:783-789, 1983.
7. Omura G, Blessing J, Ehrlich C, et al: A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. Cancer 57:1725-1730, 1986.
8. Omura GA, Bundy BA, Berek JS, et al: Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 7:457-465, 1989.
9. Gruppo Interegionale Cooperative Oncologico Ginecologia: Randomized comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Lancet 2:353-359, 1987.
10. Bertelsen K, Jakobsen A, Andersen JE, et al: A randomized study of cyclophosphamide and cisplatinum with or without doxorubicin in advanced ovarian carcinoma. Gynecol Oncol 28:161-169, 1987.
11. Conte P, Bruzzone M, Chiara S, et al: A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin and cyclophosphamide in advanced ovarian cancer. J Clin Oncol 4:965-971, 1986.
12. Hernadi Z, Juhasz B, Poka R, Lampe L: Randomized trial comparing combinations of cyclophosphamide and cisplatinum without or with doxorubicin or 4-epi-doxorubicin in the treatment of advanced ovarian cancer. Int J Gynecol Obstet 27:199-204, 1988.
13. Rozencweig M, Martin A, Beltangady M, et al: Randomized trials of carboplatin versus cisplatin in advanced ovarian cancer. In: Carboplatin (JM-8): Current Perspectives and Future Directions, edited by P Bunn, R Ozols, R Canetta, et al, Philadelphia, WB Saunders, 1990, pp 175-186.
14. Alberts DS, Green SJ, Hannigan EV, et al: Improved efficacy of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Preliminary report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV suboptimal ovarian cancer. Proc ASCO 8:151, 1989 (abstract).
15. ten Bokkel Huinink WW, van der Burg MEL, van Oosterom AT, Neijt JP, George M, Guastalla JP, Veenhof CHN, Rotmensz N, Dalesio O, Vermorken JB: Carboplatin in combination therapy for ovarian cancer. Cancer Treat Rev 15 (Suppl B):9-15, 1988.
16. Pater J: Cyclophosphamide/cisplatin versus cyclophosphamide/carboplatin in macroscopic residual ovarian cancer. Initial results of a National Cancer Institute of Canada Clinical Trials Group trial. Proc ASCO 9:155, 1990 (abstract).
17. Edmondson JH, McCormack GM, Wieand HS, et al: Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: A comparison of equally myelosuppressive regimens. J Natl Cancer Inst 81:1500-1504, 1989.
18. Skipper H: Dose intensity versus total dose of chemotherapy: An experimental basis. In: Important Advances in Oncology, edited by VT De Vita, S Hellman, S Rosenberg, JB Lippincott, 1990, pp 43-64.
19. Levin L, Hryniuk W: Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 5:756-767, 1987.
20. McGuire WP, Hoskins WJ, Brady MF, Homesley H, Clarke-Pearson DL: A phase III trial of dose intense versus standard dose cisplatin and cytoxan in advanced ovarian cancer. Proc ASCO 11:226, 1992.
21. Colombo N. Pittelli M. Parma G, et al: Cisplatin dose intensity in advanced ovarian cancer: a randomized study of conventional dose versus dose-intense cisplatin monochemotherapy. Proc ASCO 12:255, 1993.
22. Rothenberg M, Ozols R, Glatstein E, et al: Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer. J Clin Oncol 10:727-734, 1992.
23. Ozols RF, Ostchega Y, Curt G, Young RC: High-dose carboplatin in refractory ovarian cancer patients. J Clin Oncol 5:197-201, 1987.
24. Alberts DS, Young L, Mason NL, et al: In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin Oncol 12(Suppl):38-42, 1985.
25. Markman M, Reichman B, Hakes T, et al: Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 9:1801-1805, 1991.
26. Kaye SB: Importance of cisplatin dosage in advanced ovarian cancer: survival benefit in a randomised trial. Proc ASCO 11:226, 1992.
27. Alberts D, Liu P, Hannigan E, et al: Phase III study of intraperitoneal cisplatin/intravenous cyclophosphamide vs intravenous cisplatin/intravenous cyclophosphamide in patients with optimal disease stage4 III ovarian cancer: A SWOG-GOG-ECOG inter-group study. Proc ASCO 14:273, 1995.
28. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC: Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279, 1989.
29. Thigpen T, Blessing J, Ball H, Hummel S, Barrett R: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study. J Clin Oncol 12:1748-1753, 1994.
30. Einzig AI, Wiernik PH, Sasloff J, et al: Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10:1748-1753, 1992.
31. Kohn E, Sarosy G, Bicher A, et al: Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 86:18-24, 1994.
32. Swenerton K, Eisenhauer E, ten Bokkel Huinink W, et al: Taxol in relapsed ovarian cancer: high vs low dose and short vs long infusion: a European-Canadian study coordinated by the NCI Canada Clinical Trials Group. Proc ASCO 12:810, 1993 (abstract).
33. McGuire WP, Hoskins W, Brady M, et al: Taxol and cisplatin improves outcome in advanced ovarian cancer as compared to cytoxan and cisplatin. Proc ASCO 14:275, 1995.
34. Day, TG, Smith JP: Diagnosis and staging of ovarian carcinoma. Semin Oncol 2:217, 1975.
35. Young RC, Walton L, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, Miller A, Park R, Major F Jr: Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 322:1021-1027, 1990.
36. Bolis G, Colombo N, Favalli G, et al: Randomized multicenter clinical trials in stage I epithelial ovarian cancer. Proc ASCO 11:225, 1992.